BerGenBio to present interim clinical and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO

·
Four peer reviewed BerGenBio abstracts on clinical data with bemcentinib
accepted for presentation at ASCO

·
BerGenBio to host KOL reception to showcase bemcentinib studies and potential as
a cornerstone of cancer therapy
Bergen, Norway, 16 May 2018 - BerGenBio ASA (OSE:BGBIO) announces that the
company and its collaborators will present new interim clinical and biomarker
data from its extensive Phase II clinical development programme with
bemcentinib, a selective, oral AXL inhibitor, at the 2018 annual meeting of the
American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago, IL
(1-5 June 2018). Abstracts are now available online at https://am.asco.org/ and
details of the presentations are below. The posters presented at ASCO will be
made available on www.bergenbio.com in the Investors / Presentations section
following the sessions.

Presentations at ASCO

Monday 4 June, 8:00 AM - 11:30 AM Central Daylight Time (Hall A)

Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in
-class selective AXL inhibitor, in combination with pembrolizumab in patients
with advanced NSCLC.

· James Lorens, PhD et al
· Session: Developmental Therapeutics - Immunotherapy
· Poster Board: #292, Abstract 3078

Identification of predictive and pharmacodynamic biomarkers associated with the
first-in-class selective AXL inhibitor bemcentinib across multiple Phase II
clinical trials.

· Robert J Holt, PhD et al
· Session: Developmental Therapeutics - Clinical Pharmacology and
Experimental Therapeutics
· Poster Board: #385, Abstract 2559

Analysis of anti-leukemic activity, predictive biomarker candidates, immune
activation and pharmakodynamics in R/R AML and MDS in response to treatment with
bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a Phase II
open-label, multi-centre study.

· Bjørn T. Gjertsen, MD, PhD et al
· Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and
Allotransplant
· Poster Board: #80, Abstract 7020
· To be discussed at the Poster Discussion Session on Monday 4 June, 11:30 AM
- 12:45 PM, at E450

Monday 4 June, 1:15 PM - 4:45 PM CDT (Hall A)

A randomized Phase Ib/II study of the selective small molecule AXL inhibitor
bemcentinib (BGB324) in combination with either dabrafenib/trametinib or
pembrolizumab in patients with metastatic melanoma.

· Oddbjørn Straume, MD, PhD et al
· Session: Melanoma/Skin Cancers
· Poster Board: #375, Abstract 9548

BerGenBio reception

Coinciding with ASCO, BerGenBio will host a reception for collaborators,
investors, analysts, media and other interested parties on 2 June at The School
of the Art Institute Ballroom in Chicago. At this event, short presentations
will be given by clinical investigators participating in the bemcentinib
clinical trials and by KOL experts in AXL kinase function. For further details
and to receive an invitation, please click here (asco2018@bergenbio.com) or
email: asco2018@bergenbio.com.

The presentations will be made available on BerGenBio's website in the Investors
/ Presentations section following the event.

-End-

About BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class AXL kinase inhibitors as a potential
cornerstone of combination cancer therapy. The Company is a world leader in
understanding the essential role of AXL kinase in mediating aggressive disease,
including immune evasive, drug resistant, metastatic solid and haematological
cancers.

BerGenBio's lead product, bemcentinib (BGB324), is a selective, potent and
orally bio- available small molecule AXL inhibitor in four Company sponsored
Phase II clinical trials in major cancer indications, with read-outs anticipated
during 2018. It is the only selective AXL inhibitor in clinical development.

The Company sponsored clinical trials are:

· Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-
small cell lung cancer (NSCLC)
· Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the lung, and
· Bemcentinib with KEYTRUDA in triple-negative breast cancer (TNBC).
· Bemcentinib as a single agent and combination therapy in acute myeloid
leukaemia (AML) / myeloid dysplastic syndrome (MDS)

The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the
lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth,
NJ, USA), through a subsidiary.

In addition, a number of investigator-sponsored trials are underway, including a
trial to investigate bemcentinib with either MEKINIST® (trametinib) plus
TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial
combining bemcentinib with docetaxel in advanced NSCLC.

BerGenBio is simultaneously developing a companion diagnostic test to identify
patient subpopulations most likely to benefit from treatment with bemcentinib.
This will facilitate more efficient registration trials and support a precision
medicine based commercialisation strategy.

The Company is also developing a diversified pre-clinical pipeline of drug
candidates, including BGB149, an anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary
of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of
OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a
registered trademark of Novartis International AG and MEKINIST® is a registered
trademark of GSK plc.

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

International Media Relations

David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson

bergenbio@citigatedewerogerson.com

+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.